Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ:ABSI)

2.820 +0.180 (+6.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Absci (ABSI) Q3 2025 Earnings Call Transcript ↗
Absci (ABSI) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Ardent Health, KinderCare Learning, Ibotta And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Absci's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Wednesday's after hours session: top gainers and losers ↗
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
From Absci Corporation
Via GlobeNewswire
News headline image
Absci's AI Revolution: A New Era for Drug Discovery or a Rocky Road Ahead?
Absci (NASDAQ: ABSI), a pioneer in AI-driven drug discovery, is making significant strides with its "Integrated Drug Creation™ Platform," promising to revolutionize how new medicines are brought to... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk ↗
Absci's AI drug development platform is compelling, and its pipeline is promising...but can the company overcome execution hurdles to live up to analyst hype? 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
AI Revolutionizes Professional Services: A New Era for Doctors, Lawyers, and Consultants
As of October 1, 2025, Artificial Intelligence (AI) has transcended its nascent stages, becoming an indispensable force in high-value professional tasks across medicine, law, and consulting. This... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration ↗
Absci teams up with Oracle and AMD to enhance AI-driven drug discovery using high-performance GPUs. 
Via Benzinga
News headline image
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Performance and scalability of Oracle Cloud Infrastructure AI infrastructure enables Absci to accelerate biologics design cycles and reduce costs 
From Absci Corporation; Oracle; AMD
Via GlobeNewswire
News headline image
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. 
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
News headline image
Absci Sales Fall 54 Percent ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Absci Corp (NASDAQ:ABSI) Q2 2025 Earnings: Revenue Miss Sparks Market Selloff ↗
Absci Corp (ABSI) Q2 2025 earnings miss revenue estimates at $0.59M vs. $1.46M, EPS -$0.24. Stock drops 5% post-report despite strong cash position and pipeline progress. 
Via Chartmill
Topics Earnings
News headline image
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
From Absci Corporation
Via GlobeNewswire
News headline image
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
From Absci Corporation
Via GlobeNewswire
News headline image
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics ↗
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. 
Via Benzinga
News headline image
Gold Falls Over 1%; Phillips 66 Posts Upbeat Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Gapping stocks in Friday's session ↗
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.